Survival of hereditary non-polyposis colorectal cancer patients compared with sporadic colorectal cancer patients by Stigliano, Vittoria et al.
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
Journal of Experimental & Clinical 
Cancer Research
Open Access Case study
Survival of hereditary non-polyposis colorectal cancer patients 
compared with sporadic colorectal cancer patients
Vittoria Stigliano*1, Daniela Assisi1, Maurizio Cosimelli2, 
Raffaele Palmirotta3, Diana Giannarelli4, Marcella Mottolese5, 
Lupe Sanchez Mete1, Raffaello Mancini2 and Vincenzo Casale1
Address: 1Gastroenterology and Digestive Endoscopic Unit, Regina Elena Cancer Institute Via Elio Chianesi 53, 00144 Rome, Italy, 2Department 
of Surgery, Regina Elena Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy, 3Department of Laboratory Medicine and Advanced 
Biotechnologies IRCCS San Raffaele Pisana, Via della Pisana 235, 00163 Rome, Italy, 4Biostatistic Unit, Regina Elena Cancer Institute Via Elio 
Chianesi 53, 00144 Rome, Italy and 5Department of Pathology Regina Elena Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
Email: Vittoria Stigliano* - stigliano@ifo.it; Daniela Assisi - assisi@ifo.it; Maurizio Cosimelli - cosimelli@ifo.it; 
Raffaele Palmirotta - raffaele.palmirotta@sanraffaele.it; Diana Giannarelli - giannarelli@ifo.it; Marcella Mottolese - mottolese@ifo.it; 
Lupe Sanchez Mete - sanchez@ifo.it; Raffaello Mancini - cosimelli@ifo.it; Vincenzo Casale - vincenzocasale@hotmail.it
* Corresponding author    
Abstract
Background: Patients with hereditary non-poliposys colorectal cancer (HNPCC) have better
prognosis than sporadic colorectal cancer (CRC). Aim of our retrospective study was to compare
the overall survival between sporadic CRC and HNPCC patients.
Methods: We analyzed a cohort of 40 (25 males and 15 females) HNPCC cases with a hospital
consecutive series of 573 (312 males and 261 females) sporadic CRC observed during the period
1970–1993. In 15 HNPCC patients we performed mutational analysis for microsatellite instability.
Survival rates were calculated by Kaplan-Meier method and compared with log rank test.
Results: The median age at diagnosis of the primary CRC was 46.8 years in the HNPCC series
versus 61 years in sporadic CRC group. In HNPCC group 85% had a right cancer location, vs. 57%
in the sporadic cancer group. In the sporadic cancer group 61.6% were early-stages cancer (Dukes'
A and B) vs. 70% in the HNPCC group (p = ns). The crude 5-years cumulative survival after the
primary CRC was 94.2% in HNPCC patients vs. 75.3% in sporadic cancer patients (p < 0.0001).
Conclusion: Our results show that overall survival of colorectal cancer in patients with HNPCC
is better than sporadic CRC patients. The different outcome probably relates to the specific
tumorigenesis involving DNA mismatch repair dysfunction.
Background
Colorectal cancer is one of the most common neoplasm
in humans [1,2]. It's known that a definite fraction, rang-
ing between 1 and 5% of all cases of colorectal tumors, is
transmitted from one generation to another in accordance
with an autosomal dominant model; this is the case of
Hereditary Non-Polyposis Colorectal Cancer (HNPCC)
and of Familial Adenomatous Polyposis (FAP) [2].
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HNPCC is an autosomal dominant disease characterized
by early appearance of cancer usually of the right colon,
frequent occurrence of multiple lesions (both synchro-
nous and metachronous) and a striking association with
tumours of other organs, in particular endometrium, uri-
nary tract, ovary, stomach and small bowel. The Amster-
dam criteria, currently used for the diagnosis of HNPCC,
were introduced in 1989 to provide a uniform evaluation
of familial and personal history. They were revised in
1999 and included various extra-colonic tumours: 1) at
least three or more relatives with histological verified
tumour in the spectrum of HNPCC, one of whom is a
first-degree relative of the other two; 2) at least two gener-
ations should be affected; 3) one or more tumours diag-
nosed when under the age of 50 years; 4) FAP should be
excluded [3,4].
Colorectal tumours with microsatellite instability (MSI
phenotype) have mutations in mismatch repair (MMR)
genes and in particular in the MSH2 and MLH1 genes,
respectively found on chromosome arms 2p and 3p [5-9].
These mutations lead to inactivation of the genes and thus
to a defect in replication/repair of DNA and an accumula-
tion in the cancer cell genome of ubiquitous somatic
clonal mutations [10]. Constitutional mutations of MMR
genes are found in 50–70% of hereditary non-polyposis
colorectal cancer (HNPCC) and in the Muir-Torre syn-
drome; 90% of them MLH1 and MSH2 positive [11,12].
A certain proportion (around 12–15%) of sporadic colon
cancers also display MSI phenotype [13-17]. Otherwise,
MSI seems to be important in the development of various
human cancer such as sporadic endometrial cancer [18]
and oral squamous cell carcinoma [19].
Colorectal cancer (CRC) in HNPCC more often have a
better prognosis than in sporadic colorectal carcinoma
[3,4,20-22], but it has been unclear whether this could be
due to difference in stage at diagnosis or to a more favour-
able prognosis of cancer in HNPCC and FAP.
The aim of our retrospective study was to compare stage
and overall survival between patients with hereditary and
sporadic colorectal cancer patients.
Methods
We analyzed 40 HNPCC patients (25 males and 15
females) with histological verified colorectal carcinoma
and a consecutive series of 573 (312 males and 261
females) sporadic CRC patients with no familial predispo-
sition, observed and treated at the Regina Elena Cancer
Institute of Rome during the period 1970–1993 [23].
HNPCC patients were selected by both personal and
familial history (performing complete pedigree including
first and second-degree relatives) according to Amsterdam
I criteria. In 15 patients of the HNPCC group, we per-
formed mutational analysis for microsatellite instability,
investigating mutations in mismatch repair genes as
hMLH1 and hMSH2 correlated with disease. We analyzed
seven microsatellite loci: D2S123, D3S1611, and BAT-26,
D9S145, D1S158, SCZD1, and D11S905 [5,14,24,25].
All cases were pathologically staged taking into account a
total number of lymphonodes exceeding 7 (range 7 to 31,
mean 13.0, mode 11.9, standard deviation 6.2), as recom-
mended by the American Joint Committee on Cancer/
International Union Against Cancer [26].
Histological examination was performed according to
WHO criteria and carcinomas were classified according to
the Dukes' stage. Furthermore, we defined the right colon
as the tract from the cecum to the splenic flexure. The left
colon included the descending and sigmoid colon. The
rectum was defined as the rectosigmoid junction and rec-
tum.
From 1990, the rectal cancer patients clinically staged
Dukes' B and C were addressed to high-dose pelvic radio-
therapy, all the rectal cancer patients underwent a total
mesorectal excision (TME) surgery. Adjuvant i.v. chemo-
therapy was administered in all the eligible Dukes' C
colorectal cancer patients, those staged Dukes' D under-
went chemotherapy.
Patients with sporadic CRC were submitted to a yearly
colonoscopy for the first 5 years and every 2 years thereaf-
ter [23], HNPCC patients with CRC were submitted to a
yearly colonoscopy. Considering the increased risk of
extracolonic manifestations, hereditary colorectal cancer
patients were also submitted to periodical instrumental
examinations tailored to the different spectrum of the dis-
ease [4,27].
The index date for survival calculation was defined as the
date of treatment for the first colorectal cancer. Clinical
follow-up procedures provided information on the sub-
ject's status.
Statistical analysis
Survival curves were estimated using the Kaplan-Meier
method and stratified according to various clinical and
pathological variables. Differences were tested using the
log-rank test. Multivariate analysis was performed using
the Cox regression analysis.
Results
The median age at diagnosis of the primary CRC was 46.8
years in the HNPCC group versus 61 years in sporadic
CRC group. In the HNPCC group 34 patients (85%) had
colon tumours and 6 (15%) had rectal cancer. In sporadicJournal of Experimental & Clinical Cancer Research 2008, 27:39 http://www.jeccr.com/content/27/1/39
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colorectal cancer group 326 (57%) had colon tumors and
247 (43%) had rectal cancer (p = 0.0001) (Table 1).
In the sporadic cancer group 353 (61.6%) had an early-
stage cancer (94 Dukes' A and 259 Dukes' B) and 220
(38.4%) had an advanced carcinoma (123 Dukes' C and
97 Dukes' D). In the HNPCC group 28 (70%) had an early
stage cancer (9 Dukes' A and 19 Dukes' B) and 12 (30%)
had an advanced carcinoma (10 Dukes' C and 2 Dukes'
D). The difference was not statistically significant (p =
0.29) (Table 2).
The presence of synchronous or metachronous tumours
was also investigated for this population. In particular, we
did not have more than one cancer at the first diagnosis in
either the HNPCC group or sporadic CRC group. Meta-
chronous tumours were observed in 4/40 (10%) of
HNPCC tumors and in 10/573 (1.7%) of sporadic color-
ectal cancer (p = 0.001). The median observation time of
two groups is respectively 56 months for sporadic CRC
and 54 months for HNPCC.
The 5-years cumulative disease-overall survival after the
primary CRC was 94,2% in the HNPCC patients and
75.3% in the sporadic CRC ones (Figure 1) (p < 0.0001).
After stratification for Dukes' classification, survival of
Dukes' A and B cancers (considered as localized carci-
noma) was 84.3% in the sporadic cancer patients and
96.3% in the HNPCC patients. Five year survival for
Dukes'C was 63.5% and 92.8% in the sporadic CRC and
HNPCC respectively. Survival for Dukes' D was 26.6% in
the sporadic CRC but in the HNPCC group we could not
estimate survival curves by Kaplan Meier method due to
the small number of available patients. After stratification
for Dukes' stage survival remained statistically significant,
better for HNPCC versus sporadic colorectal cancer (p <
0.0001).
Considering the different localization of tumor, we strati-
fied patients by rectal and colon cancer. The cumulative
survival after 5 years of patients with rectal cancer, was
69.7% in the sporadic CRC and 83.3% in the HNPCC
patients. In colon cancer we had a cumulative survival of
79.3% and 96.3% in sporadic CRC and HNPCC respec-
tively. The log-rank test stratified by localization was sig-
nificant (p < 0.0001). When we stratified these two groups
of patients by age we did not find any difference in sur-
vival.
The multivariate analysis of the HNPCC versus CRC
groups, Dukes' stage, tumor site showed that all these
parameters independently affected disease-specific sur-
vival (p < 0.0001, p < 0.0001 and p = 0.03 respectively).
Out of 40 HNPCC patients, 15 were investigated for mic-
rosatellite instability (MSI); all resulting positive. Further-
more, the HNPCC patients with MSI (15/40) had a
survival of 100%.
Discussion
Different survival rates of patients with colorectal cancer
have been investigated in several studies [20-22,28-31].
The results are sometimes conflicting because of the dif-
ferent pathogenetic mechanism of tumorigenesis between
sporadic and familiar types of colorectal syndrome
(HNPCC in particular). These differences are probably
due to different clinical pathological characteristics of
neoplasia and genetic alterations. Two major mechanisms
of genomic instability have been identified in sporadic
colorectal cancer progression. The first, known as chromo-
somal instability (CIN), results from a series of genetic
Table 1: Distribution of colorectal cancer by site
Tumour site HNPCC Sporadic CRC
Colon 34 (85%) 326 (57%)
Rectal 6 (15%) 247 (43%)
*P = 0.0001
Table 2: Distribution of colorectal cancer by Dukes' stage
Dukes' Stage HNPCC Sporadic CRC
A 9 (22.5%) 94 (16.4%)
B 19 (47.5%) 259 (45.2%)
C 10 (25%) 123 (21.4%)
D 2 (5%) 97 (16.9%)
Overall 5-year survival of sporadic colorectal cancer (sCRC)  and Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Figure 1
Overall 5-year survival of sporadic colorectal cancer 
(sCRC) and Hereditary Nonpolyposis Colorectal 
Cancer (HNPCC).Journal of Experimental & Clinical Cancer Research 2008, 27:39 http://www.jeccr.com/content/27/1/39
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changes that involve the activation of oncogenes, such as
Ki-ras, and inactivation of tumor-suppressor genes, such
as TP53 and APC [32-34]. The second, known as micros-
atellite instability (MSI), was described in association
with hereditary nonpolyposis colorectal cancer [35-37].
The aim of our retrospective cohort study was to compare
the survival between patients with sporadic and hereditary
colorectal cancer after surgical resection. A Finnish study
[30] and a recent Lithuanian study [22] reported an
improved prognosis for HNPCC patients compared to
sporadic colorectal cancer patients, but an Italian study
could not confirm this result [28]. The localization of
tumor is an important prognostic factor for survival. In
our study right localization (from cecum to splenic flex-
ure) is significantly more represented in the HNPCC
group with respect to the sporadic colorectal cancer group
(p < 0.0001). This different anatomical distribution
between HNPCC and sporadic CRC, confirmed in litera-
ture [34,35], is one of the Amsterdam criteria for the diag-
nosis of HNPCC and determines a better prognosis, being
less aggressive.
We have considered survival, stratified by site, in the two
groups and we demonstrated that survival for rectal cancer
does not differ statistically, so the presence of rectal cancer
with a known worse prognosis and high rate of recurrence
does not influence survival of sCRC or HNPCC (p = 0.45).
The statistically significant difference of survival was for
colon cancer (right location), independent of stage at
diagnosis, between sporadic and HNPCC cancer (p <
0.0001).
Furthermore, in order to have a better definition of popu-
lation in the study, we considered several clinical features
such as the presence of synchronous or metachronous
tumors. None of these features were represented suffi-
ciently enough in either of the groups as to influence sur-
vival rates.
The 5 years cumulative survival in HNPCC and in spo-
radic colorectal cancer was 94.2% versus 75.3% respec-
tively. This difference was statistically significant (p <
0.0001). These results do not confirm the observations
previously reported by Bertario et al [31] where 5 years
cumulative survival in HNPCC, FAP and sporadic colorec-
tal cancer groups was not statistically different. Otherwise,
our results conflicts with those of Barnetson et al [21], in
which survival was not significantly different among car-
riers and non-carriers of MMR mutations in a series of
early colorectal cancer patients. However, after stratifica-
tion for Dukes' stage survival remained statistically signif-
icant, better for HNPCC versus sporadic colorectal cancer
(p < 0.0001). In our study the stage distribution was not
significantly different between the two groups (sCRC ver-
sus HNPCC), 61.6% vs. 70% and 38.4% vs. 30% respec-
tively (p = 0.29), demonstrating that it did not influence
the overall survival between the two groups.
Myrhoj et al [29] reported an improved prognosis of can-
cer in patients with HNPCC versus sporadic CRC, but in
the HNPCC series included a high proportion of localized
tumors and this indicated that the good prognosis was
based on a more favourable stage at diagnosis. Several
studies described a trend toward prolonged survival and
better prognosis in patients with mutations or MSI in
HNPCC, revealing the presence of distinct biological fea-
tures of colon cancer in families with or without muta-
tions [25], though, as above mentioned, it was not
observed by other authors [21]. In our study 15 HNPCC
patients had positive MSI mutational analysis; overall sur-
vival of this series of patients was 100%.
Conclusion
In conclusion, our findings appear to confirm previous
studies [30,31] which detected that an improved survival
for colon cancer in HNPCC, compared to sporadic CRC,
usually occur. In fact, our series of HNPCC patients
reveals a marked overall survival advantage, which per-
sisted also after stratification by Dukes' stage. Therefore,
survival of HNPCC patients not always depends on an
early diagnosis, but probably also on distinct biologic fea-
tures. In this context, MSI mutation pattern plays an
important prognostic role since colon cancer with MSI has
a better prognosis than tumours without MSI. A large
series of HNPCC should be examined to confirm this
data. Furthermore, we need more information about MSI
in all kind of colorectal carcinomas, in order to establish
postoperative surveillance thus improving patients' prog-
nosis and allowing clinicians to plan more accurate and
targeted therapy.
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